IDX-1197+Irinotecan
Small molecule
IDX-1197+Irinotecan is one of 15 small molecule programs targeting Gastric Cancer. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Perjeta
RochePhase 3
Bemarituzumab
AmgenPhase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
CEA-Targeted CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IDX-1197+Irinotecan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- IIdience Co., Ltd.